{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:33:55Z","timestamp":1791999235768,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04288-6","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:30:58Z","timestamp":1772019058000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium"],"prefix":"10.1007","volume":"75","author":[{"given":"Takafumi","family":"Yanagisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tsujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Maenosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhisa","family":"Nukaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Morinaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Bekku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoo","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Komura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"JK-FOOT study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"4288_CR1","doi-asserted-by":"publisher","first-page":"101210","DOI":"10.1016\/j.esmoop.2023.101210","volume":"8","author":"J Haanen","year":"2023","unstructured":"Haanen J, Larkin J, Choueiri TK et al (2023) Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the international metastatic renal cell carcinoma database consortium risk group in patients with advanced renal cell carcinoma. ESMO Open 8:101210","journal-title":"ESMO Open"},{"key":"4288_CR2","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289\u20131300","journal-title":"N Engl J Med"},{"key":"4288_CR3","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","volume":"23","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Powles T, Burotto M et al (2022) Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol 23:888\u2013898","journal-title":"Lancet Oncol"},{"key":"4288_CR4","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","volume":"20","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Rini BI, McDermott DF et al (2019) Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 20:1370\u20131385","journal-title":"Lancet Oncol"},{"key":"4288_CR5","doi-asserted-by":"crossref","first-page":"LBA4501-LBA4501","DOI":"10.1200\/JCO.22.01992","volume":"41","author":"ER Plimack","year":"2023","unstructured":"Plimack ER, Stus V, Gafanov R et al (2023) Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. J Clin Oncol 41:LBA4501\u2013LBA4501","journal-title":"J Clin Oncol"},{"key":"4288_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","volume":"82","author":"B Ljungberg","year":"2022","unstructured":"Ljungberg B, Albiges L, Abu-Ghanem Y et al (2022) European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 82:399\u2013410","journal-title":"Eur Urol"},{"key":"4288_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02878-z","author":"K Mori","year":"2025","unstructured":"Mori K, Yanagisawa T, Kawada T et al (2025) Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumab. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-025-02878-z","journal-title":"Int J Clin Oncol"},{"key":"4288_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00262-020-02684-8","volume":"70","author":"K Mori","year":"2021","unstructured":"Mori K, Mostafaei H, Miura N et al (2021) Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. Cancer Immunol Immunother 70:265\u2013273","journal-title":"Cancer Immunol Immunother"},{"key":"4288_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","volume":"4","author":"F Quhal","year":"2021","unstructured":"Quhal F, Mori K, Bruchbacher A et al (2021) First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol 4:755\u2013765","journal-title":"Eur Urol Oncol"},{"key":"4288_CR10","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s00345-023-04412-0","volume":"41","author":"T Yanagisawa","year":"2023","unstructured":"Yanagisawa T, Kawada T, Quhal F et al (2023) Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis. World J Urol 41:1763\u20131774","journal-title":"World J Urol"},{"key":"4288_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00262-023-03621-1","volume":"73","author":"T Yanagisawa","year":"2024","unstructured":"Yanagisawa T, Mori K, Matsukawa A et al (2024) Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data. Cancer Immunol Immunother 73:38","journal-title":"Cancer Immunol Immunother"},{"key":"4288_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/14740338.2020.1811226","volume":"19","author":"F Massari","year":"2020","unstructured":"Massari F, Mollica V, Rizzo A et al (2020) Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opin Drug Saf 19:1329\u20131338","journal-title":"Expert Opin Drug Saf"},{"key":"4288_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bju.16336","volume":"134","author":"T Yanagisawa","year":"2024","unstructured":"Yanagisawa T, Kawada T, Bekku K et al (2024) First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy. BJU Int 134:323\u2013336","journal-title":"BJU Int"},{"key":"4288_CR14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s11912-022-01196-1","volume":"24","author":"YW Chen","year":"2022","unstructured":"Chen YW, Rini BI (2022) Approaches to first-line therapy for metastatic clear cell renal cell carcinoma. Curr Oncol Rep 24:695\u2013702","journal-title":"Curr Oncol Rep"},{"key":"4288_CR15","doi-asserted-by":"publisher","first-page":"LBA531-LBA531","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA531","volume":"42","author":"AB Apolo","year":"2024","unstructured":"Apolo AB, Ballman KV, Sonpavde GP et al (2024) AMBASSADOR alliance A031501: phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation. J Clin Oncol 42:LBA531\u2013LBA531","journal-title":"J Clin Oncol"},{"key":"4288_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"4288_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:150\u2013161","journal-title":"Pharm Stat"},{"key":"4288_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jamacardio.2020.0239","volume":"5","author":"LY Sun","year":"2020","unstructured":"Sun LY, Gaudino M, Chen RJ et al (2020) Long-term outcomes in patients with severely reduced left ventricular ejection fraction undergoing percutaneous coronary intervention vs coronary artery bypass grafting. JAMA Cardiol 5:631\u2013641","journal-title":"JAMA Cardiol"},{"key":"4288_CR19","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1002\/sim.5705","volume":"32","author":"PC Austin","year":"2013","unstructured":"Austin PC (2013) The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med 32:2837\u20132849","journal-title":"Stat Med"},{"key":"4288_CR20","first-page":"101727","volume":"55","author":"M Sun","year":"2023","unstructured":"Sun M, Chen WM, Wu SY et al (2023) Dementia risk after major elective surgery based on the route of anaesthesia: a propensity score-matched population-based cohort study. EClin Med 55:101727","journal-title":"EClin Med"},{"key":"4288_CR21","doi-asserted-by":"publisher","first-page":"938.e1","DOI":"10.1016\/j.urolonc.2020.09.024","volume":"38","author":"T Yanagisawa","year":"2020","unstructured":"Yanagisawa T, Miki J, Shimizu K et al (2020) Functional and oncological outcome of percutaneous cryoablation versus laparoscopic partial nephrectomy for clinical T1 renal tumors: a propensity score-matched analysis. Urol Oncol 38:938.e1-938.e7","journal-title":"Urol Oncol"},{"key":"4288_CR22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829\u2013841","journal-title":"N Engl J Med"},{"key":"4288_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1200\/JCO.2025.43.5_suppl.439","volume":"43","author":"RJ Motzer","year":"2025","unstructured":"Motzer RJ, Escudier B, Burotto M et al (2025) Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): final follow-up results from the CheckMate 9ER trial. J Clin Oncol 43:439\u2013439","journal-title":"J Clin Oncol"},{"key":"4288_CR24","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.23.01569","volume":"42","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Porta C, Eto M et al (2024) Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of Clear, a phase III study. J Clin Oncol 42:1222\u20131228","journal-title":"J Clin Oncol"},{"key":"4288_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00262-025-04019-x","volume":"74","author":"C Porta","year":"2025","unstructured":"Porta C, Massari F, Taha T et al (2025) Pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: real-world evidences from the international ARON-1 study. Cancer Immunol Immunother 74:196","journal-title":"Cancer Immunol Immunother"},{"key":"4288_CR26","doi-asserted-by":"publisher","first-page":"1605282","DOI":"10.3389\/fonc.2025.1605282","volume":"15","author":"MT Bourlon","year":"2025","unstructured":"Bourlon MT, Galli L, Grande E et al (2025) Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study. Front Oncol 15:1605282","journal-title":"Front Oncol"},{"key":"4288_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16172998","author":"T Hilser","year":"2024","unstructured":"Hilser T, Darr C, Niegisch G et al (2024) Cabozantinib plus nivolumab in adult patients with advanced or metastatic renal cell carcinoma: a retrospective, non-interventional study in a real-world cohort\/GUARDIANS project. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16172998","journal-title":"Cancers (Basel)"},{"key":"4288_CR28","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s10147-024-02633-w","volume":"29","author":"T Hara","year":"2024","unstructured":"Hara T, Suzuki K, Okamura Y et al (2024) Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan. Int J Clin Oncol 29:1931\u20131936","journal-title":"Int J Clin Oncol"},{"key":"4288_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaf122","author":"T Sazuka","year":"2025","unstructured":"Sazuka T, Murakami K, Nihei H et al (2025) Consecutive real-world treatment experience with a reduced starting dose of lenvatinib (14\u00a0mg) plus pembrolizumab for metastatic renal cell carcinoma. Jpn J Clin Oncol. https:\/\/doi.org\/10.1093\/jjco\/hyaf122","journal-title":"Jpn J Clin Oncol"},{"key":"4288_CR30","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.21873\/anticanres.16927","volume":"44","author":"C Nagahisa","year":"2024","unstructured":"Nagahisa C, Yoshida K, Kondo H et al (2024) Advanced renal cell carcinoma with inferior vena cava thrombus treated with a combination of preoperative lenvatinib and pembrolizumab. Anticancer Res 44:1317\u20131321","journal-title":"Anticancer Res"},{"key":"4288_CR31","unstructured":"Panian J, Zhong C, Choi SH, et al. (2024) Efficacy of treatments after lenvatinib in patients with advanced renal cell carcinoma. Eur Urol Focus"},{"key":"4288_CR32","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794\u20135799","journal-title":"J Clin Oncol"},{"key":"4288_CR33","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/MOU.0000000000000867","volume":"31","author":"K Mori","year":"2021","unstructured":"Mori K, Schmidinger M, Quhal F et al (2021) What is next in second- and later-line treatment of metastatic renal cell carcinoma? Review of the recent literature. Curr Opin Urol 31:276\u2013284","journal-title":"Curr Opin Urol"},{"key":"4288_CR34","doi-asserted-by":"publisher","first-page":"374.e21","DOI":"10.1016\/j.urolonc.2024.06.013","volume":"42","author":"T Yanagisawa","year":"2024","unstructured":"Yanagisawa T, Mori K, Kawada T et al (2024) First-line therapy for metastatic renal cell carcinoma: a propensity score-matched comparison of efficacy and safety. Urol Oncol 42:374.e21-374.e29","journal-title":"Urol Oncol"},{"key":"4288_CR35","doi-asserted-by":"publisher","first-page":"e1009","DOI":"10.1097\/01.JU.0001110068.14710.ff.15","volume":"213","author":"K Nakamura","year":"2025","unstructured":"Nakamura K, Kondo H, Nemoto Y et al (2025) MP28-15 Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. J Urol 213:e1009","journal-title":"J Urol"},{"key":"4288_CR36","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1200\/JCO.2025.43.5_suppl.470","volume":"43","author":"C Brown-Bickerstaff","year":"2025","unstructured":"Brown-Bickerstaff C, Conkling PR, Banuelos R et al (2025) Real-world (RW) treatment (tx) patterns and clinical outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) in the US community setting. J Clin Oncol 43:470\u2013470","journal-title":"J Clin Oncol"},{"key":"4288_CR37","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Powles T, Peltola K et al (2024) Belzutifan versus everolimus for advanced renal-cell carcinoma. N Engl J Med 391:710\u2013721","journal-title":"N Engl J Med"},{"key":"4288_CR38","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.eururo.2020.10.006","volume":"79","author":"K Mori","year":"2021","unstructured":"Mori K, Abufaraj M, Mostafaei H et al (2021) The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis. Eur Urol 79:783\u2013792","journal-title":"Eur Urol"},{"key":"4288_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41585-022-00676-0","volume":"20","author":"M Rosellini","year":"2023","unstructured":"Rosellini M, Marchetti A, Mollica V et al (2023) Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol 20:133\u2013157","journal-title":"Nat Rev Urol"},{"key":"4288_CR40","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.annonc.2024.12.003","volume":"36","author":"RJ Motzer","year":"2025","unstructured":"Motzer RJ, Porta C, Eto M et al (2025) Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma. Ann Oncol 36:375\u2013386","journal-title":"Ann Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04288-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04288-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04288-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:31:03Z","timestamp":1772019063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04288-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4288"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04288-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takahiro Kimura has received consulting or advisory fees from Astellas, Bayer, Janssen, Sanofi, and Takeda. The other authors declare no conflicts of interest related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of the principal institution, Osaka Medical and Pharmaceutical University (approval number: RIN\u2013750\u20132571).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived due to retrospective nature.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was waived due to retrospective nature.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"84"}}